Immix Biopharma, Inc. (IMMX): Insider Trading, Congress Trades & Research | Tormere

IMMX

$8.06+11.94%visit website

Immix Biopharma, Inc.

Market Cap

$577M

Live price × SEC shares (Aug 3, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.26

58mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

2.5

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	4,584	5,727	5,980	5,333	21,625
Total operating expenses	7,663	10,893	10,804	12,456	41,816
Operating income	(7,663)	(10,893)	(10,804)	(12,456)	(41,816)
Pretax income	(7,578)	(10,677)	(10,087)	(11,543)	(39,884)
Income tax	7.7	11.3		14.3
Net income	(7,586)	(10,649)	(10,087)	(11,557)	(39,879)
EPS (basic) ($)	(0.24)		(0.18)	(0.18)	—
EPS (diluted) ($)	(0.24)		(0.18)	(0.18)	—
Weighted avg. shares (basic)	31,927		55,369	63,771
Weighted avg. shares (diluted)	31,927		55,369	63,771

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 7, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 18 more quarters, back to Mar 2021, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

No Form 4 transactions on record.

Recent News

Immix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026

Yahoo · 2026-11-04

Immix Biopharma To Present An NXC-201 Abstract At American Society Of Hematology Annual Meeting, December 12-15

Benzinga · 2026-11-04

Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?

Yahoo · 2026-10-27

Immix Biopharma (IMMX) Stock Sees Modest Fair Value Lift After Split Analyst Revisions

Yahoo · 2026-10-21

Understanding Momentum Shifts in (IMMX)

Stock Traders Daily · 2026-10-08

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

Yahoo Finance · 2026-10-05

Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study

Yahoo Finance · 2026-10-05

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

Yahoo Finance · 2026-09-30

Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial

Yahoo Finance · 2026-09-29

Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis

Yahoo Finance · 2026-09-29

BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock

Stocktwits · 2026-09-29

All 25 new patients had a complete response or tested negative for remaining disease

Stock Titan · 2026-09-29

IMMX Forecast — Price Target — Prediction for 2027

TradingView · 2026-06-25

Is Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks?

Yahoo Finance · 2026-05-05

We Think Immix Biopharma (NASDAQ:IMMX) Can Afford To Drive Business Growth

Yahoo Finance · 2026-05-05

Informational purposes only, not investment advice.